已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept

阿柏西普 血管抑制剂 医学 自然科学 眼科 视力 糖尿病性黄斑水肿 耐火材料(行星科学) 曲安奈德 养生 贝伐单抗 糖尿病性视网膜病变 外科 糖尿病 化疗 内分泌学 天体生物学 物理
作者
Hiromi Ohara,Yosuke Harada,Tomona Hiyama,Ayako Sadahide,Akira Minamoto,Yoshiaki Kiuchi
出处
期刊:Medicina-lithuania [Multidisciplinary Digital Publishing Institute]
卷期号:59 (6): 1125-1125 被引量:48
标识
DOI:10.3390/medicina59061125
摘要

Background and Objectives: Faricimab is the first intravitreal injection of vascular endothelial growth factor-A and angiopoietin-2 bispecific monoclonal antibody. Here, we evaluate the functional and anatomical outcomes of faricimab treatment in patients with diabetic macular edema (DME) that was refractory to ranibizumab or aflibercept. Materials and Methods: We performed a retrospective, observational, consecutive-case study of patients who had DME that was refractory to treatment with ranibizumab or aflibercept and were treated with faricimab between July 2022 and January 2023 under a pro re nata regimen. All the participants were followed for ≥4 months after the initiation of faricimab. The primary outcome was a recurrence interval of ≥12 weeks, and the secondary outcomes were the changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT). Results: We analyzed 18 eyes of 18 patients. The mean recurrence interval of previous anti-VEGF injection was 5.8 ± 2.5 weeks, which was significantly extended to 10.8 ± 4.9 weeks (p = 0.0005) by the switch to faricimab. Eight patients (44.4%) achieved a recurrence interval of ≥12 weeks. A history of subtenon injection of triamcinolone acetonide (p = 0.0034) and the presence of disorganization of the retinal inner layers (p = 0.0326) were found to be significantly associated with a recurrence interval of <12 weeks. The mean BCVAs were 0.23 ± 0.28 logMAR and 0.19 ± 0.23 logMAR, and the mean CMTs were 473.8 ± 222.0 µm and 381.3 ± 219.4 µm at baseline and 4 months, respectively, but these changes were not statistically significant. None of the patients experienced serious adverse events. Conclusions: Faricimab may extend the treatment interval for patients with DME that is refractory to ranibizumab or aflibercept. DME previously treated with the subtenon injection of triamcinolone acetonide or associated with disorganization of the retinal inner layers may be less likely to be associated with a longer recurrence interval after switching to faricimab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
领导范儿的应助被zy采纳,获得10
刚刚
Random完成签到,获得积分10
1秒前
无极微光的应助被kk采纳,获得20
1秒前
cdercder的应助被聪明紫山采纳,获得10
2秒前
Shaw完成签到,获得积分10
2秒前
MingWang发布了新的文献求助10
2秒前
李健的应助被ZZC采纳,获得10
3秒前
科研通AI6.4的应助被活着采纳,获得10
3秒前
3秒前
zcz发布了新的文献求助10
4秒前
5秒前
大只仙仙完成签到,获得积分10
8秒前
8秒前
花生了树发布了新的文献求助10
8秒前
9秒前
小怡完成签到 ,获得积分10
9秒前
Yeee1226发布了新的文献求助10
10秒前
syvshc的应助被MingWang采纳,获得10
11秒前
zcaw发布了新的文献求助10
11秒前
14秒前
14秒前
搜集达人的应助被zcaw采纳,获得10
14秒前
bkagyin的应助被沐染采纳,获得10
15秒前
15秒前
阳阳来袭完成签到,获得积分10
17秒前
ou发布了新的文献求助10
19秒前
19秒前
JamesPei的应助被科研通管家采纳,获得10
19秒前
完美世界的应助被科研通管家采纳,获得10
19秒前
zy发布了新的文献求助10
19秒前
无极微光的应助被科研通管家采纳,获得20
19秒前
VDC的应助被科研通管家采纳,获得30
19秒前
19秒前
19秒前
wanci的应助被科研通管家采纳,获得10
20秒前
20秒前
20秒前
Lucas的应助被科研通管家采纳,获得20
20秒前
李爱国的应助被科研通管家采纳,获得10
20秒前
隐形曼青的应助被科研通管家采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194529
求助须知:如何正确求助?哪些是违规求助? 9580304
关于积分的说明 21870538
捐赠科研通 7794101
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484393